SLAS Welcomes Three New Members to the 2026 Board of Directors

Melanie Leveridge — AstraZeneca, UK
Leveridge is the Vice President of Assays, Profiling & Cell Sciences at AstraZeneca, where she leads teams across Cambridge (UK), Sweden and Boston accountable for generation of cellular reagents, assay development, compound profiling and mechanism of action studies to progress AstraZeneca’s discovery portfolio. Her involvement with SLAS began in 2010, and since then she has served in many roles, including conference speaker, scientific session chair, scientific track chair; member and chair of the Americas Scientific Program Committee (ASPC) and SLAS International Conference & Exhibition Chair (2020). She has also served as a reviewer for SLAS Discovery journal and as a judge for the Innovation Award, giving her a deep familiarity with the SLAS community. With her experience spanning global biopharma and connections to the UK life sciences ecosystem, Leveridge is passionate about transforming research through collaboration and innovation.

Brinton Seashore-Ludlow, PhD — Karolinska Institutet, Sweden
Seashore-Ludlow is a Senior Researcher at Karolinska Institutet, where she focuses on high-content screening in near-patient models, and serves as Head of the Assay Development and Screening team at the Chemical Biology Consortium Sweden, a national infrastructure for chemical biology services. She has been actively engaged in SLAS through roles including vice-chair and chair of the European Scientific Planning Committee, scientific session chair at SLAS Europe Conference & Exhibition (2019), Co-chair of SLAS Europe 2022 and more. She is currently contributing to the European planning team for SLAS Europe 2026. Seashore-Ludlow brings extensive leadership experience, deep domain knowledge, an active network and a proven track record of serving the SLAS community.

Hervé Tiriac, PhD — University of California San Diego, USA
Tiriac is an Assistant Research Scientist in the Department of Surgery at the University of California San Diego Health, where his laboratory pioneers patient-derived 3-D cultures and multi-cellular co-culture platforms to uncover and overcome drug resistance in cancer. Within SLAS, he has co-organized 3D modeling-focused symposia content, served as a Short Course instructor,, served as associate and scientific track chair for two annual international conferences, co-chaired the 2025 SLAS International Conference & Exhibition, , served on the SLAS Discovery editorial board as an Associate Editor, and serves on the Americas Scientific Program Committee (ASPC) and Knowledge Content and Delivery Council (KCDC). During his tenure with SLAS, Tiriac has championed diverse voices and emerging technologies and built content suited for academia, biotech and pharma.

President
Melissa Crisp, PhD
Eli Lilly and Company
USA

Vice President
Madhu Lal-Nag, PhD
InSphero AG
Switzerland

Secretary
Marybeth Burton, MS
Merck
USA

Treasurer
Zachary A. Gurard-Levin, PhD*
Peapod Bio
USA

Director
David K. Jennions, PhD
Grail
USA

Director
Glauco R. Souza, PhD
Greiner Bio-One
USA